Metsera Inc (MTSR) reported disappointing financial results for the third quarter of fiscal 2025, with an earnings per share (EPS) of $-1.11, falling short of Wall Street's consensus estimate of $-0.74 by $0.37. Revenue remained at $0.0B, matching analysts' expectations but indicating a lack of growth.
The company's weak performance raises concerns about its operational challenges and market conditions. Metsera, a clinical-stage biopharmaceutical company based in New York City, is focused on developing next-generation injectable and oral nutrient-stimulated hormone analog peptides to address obesity and related conditions. Its product pipeline includes advanced candidates such as MET-097i, a long-acting GLP-1 receptor agonist, and MET-233i, an amylin analog.
The company plans to host an earnings conference call to discuss these results and provide further insights into its business performance. Investors are encouraged to review the full earnings release and management commentary for a comprehensive understanding of the quarter's results and future outlook.
With a current market cap of $8.8B and a trailing twelve-month EPS of $-3.71, Metsera is poised to face scrutiny as it approaches its next earnings report scheduled for May 10, 2026, where analysts estimate an EPS of $-0.93 and revenue of $0.